TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07227896: Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Sponsor: AbbVie · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,707,200

Rescue Site Savings

+$1,125,200

Unlock Full NCT07227896 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227896 Rescue Dossier →